Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

ATXI

Avenue Therapeutics (ATXI)

Avenue Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ATXI
FechaHoraFuenteTítuloSímboloCompañía
16/05/202407:30GlobeNewswire Inc.Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)NASDAQ:ATXIAvenue Therapeutics Inc
15/05/202408:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATXIAvenue Therapeutics Inc
15/05/202407:30GlobeNewswire Inc.Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:ATXIAvenue Therapeutics Inc
12/05/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATXIAvenue Therapeutics Inc
10/05/202415:53Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ATXIAvenue Therapeutics Inc
10/05/202415:52Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATXIAvenue Therapeutics Inc
29/04/202407:00GlobeNewswire Inc.Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross ProceedsNASDAQ:ATXIAvenue Therapeutics Inc
24/04/202406:30GlobeNewswire Inc.Avenue Therapeutics Announces Reverse Stock SplitNASDAQ:ATXIAvenue Therapeutics Inc
25/03/202407:30GlobeNewswire Inc.Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024NASDAQ:ATXIAvenue Therapeutics Inc
18/03/202415:05GlobeNewswire Inc.Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:ATXIAvenue Therapeutics Inc
15/03/202407:15GlobeNewswire Inc.Avenue Therapeutics Receives Positive Listing Determination from NasdaqNASDAQ:ATXIAvenue Therapeutics Inc
11/03/202407:00GlobeNewswire Inc.Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual MeetingNASDAQ:ATXIAvenue Therapeutics Inc
08/03/202415:31Edgar (US Regulatory)Form PRE 14C - Other preliminary information statementsNASDAQ:ATXIAvenue Therapeutics Inc
22/02/202407:30GlobeNewswire Inc.Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence EpilepsyNASDAQ:ATXIAvenue Therapeutics Inc
29/01/202407:00Edgar (US Regulatory)Form DEF 14C - Other definitive information statementsNASDAQ:ATXIAvenue Therapeutics Inc
24/01/202415:11Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ATXIAvenue Therapeutics Inc
11/01/202407:00GlobeNewswire Inc.Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor ConferenceNASDAQ:ATXIAvenue Therapeutics Inc
05/01/202408:15GlobeNewswire Inc.Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in ProceedsNASDAQ:ATXIAvenue Therapeutics Inc
04/01/202407:30GlobeNewswire Inc.Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV TramadolNASDAQ:ATXIAvenue Therapeutics Inc
02/01/202407:30GlobeNewswire Inc.Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)NASDAQ:ATXIAvenue Therapeutics Inc
13/12/202315:03Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ATXIAvenue Therapeutics Inc
13/12/202315:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATXIAvenue Therapeutics Inc
01/12/202307:30GlobeNewswire Inc.Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual MeetingNASDAQ:ATXIAvenue Therapeutics Inc
28/11/202315:05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ATXIAvenue Therapeutics Inc
28/11/202315:01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ATXIAvenue Therapeutics Inc
13/11/202315:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATXIAvenue Therapeutics Inc
13/11/202315:05GlobeNewswire Inc.Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:ATXIAvenue Therapeutics Inc
02/11/202314:00GlobeNewswire Inc.Avenue Therapeutics Announces Closing of $5.0 Million Public OfferingNASDAQ:ATXIAvenue Therapeutics Inc
02/11/202308:00Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:ATXIAvenue Therapeutics Inc
31/10/202308:15GlobeNewswire Inc.Avenue Therapeutics Announces Pricing of $5.0 Million Public OfferingNASDAQ:ATXIAvenue Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ATXI

Su Consulta Reciente

Delayed Upgrade Clock